Background: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed.
Introduction
The incidence of melanoma is increasing, with up to 20% of patients expected to develop advanced/metastatic disease [1] . The historical 10-year survival rate in patients with advanced melanoma was approximately 10% [2] [3] [4] ; experience with monotherapy directed against cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) [5] [6] [7] has increased this survival rate up to 22% [4] . Given the increased response and 1-year survival rates with programmed death (PD-1) inhibitors [8] [9] [10] [11] [12] , a complementary increase in 5-year survival is expected.
Two PD-1 inhibitors, pembrolizumab and nivolumab, have been evaluated extensively in patients with melanoma; both block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, to reinstate the antitumor immune response [13, 14] . In three separate trials of advanced melanoma (KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006), which included previously treated and treatment-naive patients, pembrolizumab monotherapy provided durable response rates of 30%-40% [8, 10, 12, [15] [16] [17] [18] . Similarly, in the advanced melanoma cohort of patients from the dose-ranging phase I CA209-003 study, treatment with nivolumab resulted in a cumulative response rate of 28% [19] and 5-year overall survival (OS) rate of 34% [20] . Subsequent phase III studies of nivolumab as monotherapy in treatment-naive and previously treated advanced melanoma yielded durable response rates of 32% and 40%, respectively [9, 11] . Reports of long-term efficacy and safety in patients treated with PD-1 inhibitors for advanced melanoma are limited.
In the large phase Ib KEYNOTE-001 study, pembrolizumab monotherapy provided 3-year OS rates of 41% for patients with ipilimumab-treated and ipilimumab-naive advanced melanoma and 45% for patients with treatment-naive advanced melanoma [12] . Median OS was 23.8 months (95% CI, 20.2-29.0) overall and 20.0 (95% CI, 17.8-27.1), and 28.8 (95% CI, 23.1-32.2) months for ipilimumab-treated and treatment-naive patients, respectively. Five-year follow-up data of patients treated with pembrolizumab are presented, including data on retreatment of patients receiving a second-course of pembrolizumab on disease progression after first course therapy.
Patients and methods
Patients KEYNOTE-001 (NCT01295827) was an open-label, phase Ib clinical trial that included multiple cohorts of patients with advanced solid tumors, including melanoma and non-small-cell lung cancer. Eligibility criteria for the ipilimumab-treated or ipilimumab-naive melanoma cohorts are published [8] . Briefly, eligible patients were 18 years of age with confirmed advanced or metastatic melanoma, measurable disease per immune-related response criteria (irRC) [21] , Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1, no history of chemotherapy within 4 weeks of first pembrolizumab dose, and no history of treatment targeting the PD-1/PD-L1 pathway. Patients were recruited between December 2011 and September 2013, and they enrolled in nonrandomized and randomized cohorts.
Study design
The study protocol and amendments were approved by the appropriate institutional review board or independent ethics committee at each participating institution. The study was conducted in accordance with the protocol, good clinical practice guidelines, provisions of the Declaration of Helsinki, and all local regulations. All patients provided written informed consent to participate.
Treatment and assessments
Patients received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient or investigator decision to withdraw. After a protocol amendment, patients who experienced complete response (CR), confirmed by imaging scans 4 weeks apart, and who received pembrolizumab treatment for 6 months could, at the discretion of the investigator and if the patient desired, discontinue treatment after receiving 2 pembrolizumab doses beyond the initial determination of CR. Patients were eligible to receive a second course of pembrolizumab if they stopped initial treatment after attaining investigator-determined CR per irRC, investigator-determined partial response (PR), or stable disease (SD) after 2 years of treatment with pembrolizumab; were treated for 24 weeks before discontinuing therapy; experienced investigatordetermined progression after stopping their initial treatment; had an ECOG status of 0 or 1; and did not receive any cancer treatment since the last dose of pembrolizumab. Tumor response was assessed every 12 weeks by independent central review using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (for determining efficacy) and by investigator review using irRC (for disease management). For all analyses of response rates and PFS, tumor response was assessed by investigator review using irRC; for the biomarker analyses, response was assessed by central review per RECIST v1.1.
Gene expression analysis
The correlation between response to pembrolizumab and gene expression profile (GEP) was explored using the 18-gene T-cell-inflamed GEP [CCL5, CD27, CD274 (PD-L1), CD276 (B7-H3), CD8A, CMKLR1, CXCL9, CXCR6, HLA-DQA1, HLA-DRB1, HLA-E, IDO1, LAG3, NKG7, PDCD1LG2 (PD-L2), PSMB10, STAT1, and TIGIT]; development is described elsewhere [22] . The 18-gene T-cell-inflamed GEP consists of genes related to antigen presentation, chemokine expression, cytolytic activity, and adaptive immune resistance. GEP scores were computed by taking a weighted sum of the housekeeping-normalized values of the 18 genes on the GEP18 signature.
Statistical analysis
All analyses were performed in the treated population, defined as all patients who received 1 dose of pembrolizumab. The Kaplan-Meier (KM) method was used to estimate the OS curve in each patient population; the nonparametric KM method was used to estimate the progression-free survival (PFS) curve in each treatment and duration of response. Duration of response was calculated from time of first response to time of progression. Patients without a progression event were censored at the date of the last non-PD assessment. Best overall response (BOR) was based on investigator assessment. Analyses were performed using a data cut-off date of September 1, 2017.
Results KEYNOTE-001 enrolled 655 patients in the melanoma cohorts; of these, 151 were treatment-naive and 496 were previously treated (205 received 1 prior therapy, 178 received 2 prior therapies, 113 received 3 prior therapies); 8 patients had uveal melanoma and had received no prior systemic therapy. Baseline characteristics according to treatment group are published and were well balanced [8] . Supplementary Table S1 , available at Annals of Oncology online, presents baseline characteristics in the melanoma cohorts. Median duration of follow-up was 55 months (range: 48-69), and median duration of exposure to pembrolizumab was 5.6 months (range: 1 day-67 months). At data cut-off, 33 (5%) patients, including 2 on second course, were still receiving treatment, and 569 patients (87%) discontinued because of progressive disease (PD; n ¼ 275; 42%), adverse events (n ¼ 166; 25%), physician decision (n ¼ 80; 12%), patient withdrawal (n ¼ 36; 5%), protocol violation (n ¼ 8; 1%), or lost to follow-up (n ¼ 4; <1%) (supplementary Table S2 , available at Annals of Oncology online).
At data cut-off, 63% (n ¼ 412) of all patients and 54% (n ¼ 81) of treatment-naive patients had died. The estimated 5-year OS rate was 34% in all patients and 41% in treatment-naive patients. Median OS was 23.8 months (95% CI, 20.2-30.4) in all patients and 38.6 months (95% CI, 27.2-NR) in treatment-naive patients ( Figure 1A and B). The 5-year estimated PFS rate was 21% and 29%, respectively. Median PFS was 8.3 months (95% CI, 5.8-11.1) in all patients and 16.9 months (95% CI, 9.3-35.5) in treatmentnaive patients ( Figure 1C and D) .
Among all 655 treated patients, 104 (16%) achieved CR, 163 (25%) achieved PR, and 156 (24%) achieved SD, for a disease control rate (DCR) of 65% (Table 1; Figure 2 ). In total, 164 (25%) patients experienced a BOR of PD. Of the 423 patients who contributed to the DCR, 165 (13 CR, 61 PR, 91 SD) experienced subsequent disease progression. Median time to response was 2.8 months (range: 0.5-49.6), and median duration of response was NR (range: 1.3þ to 66.3þ months) (supplementary Figure  S1A , available at Annals of Oncology online). Of those who achieved CR, median time to response was 2.8 months (range: 0.5-11.0), and median duration of response was NR (range: 3.8þ to 66.3þ months). Response was ongoing in 89% (n ¼ 93) of patients who achieved CR. In patients with PR, median time to response was 2.8 months (range: 1.7-49.6), and median duration of response was NR (range: 1.3þ to 63.5þ months). At data cut-off, response was ongoing in 63% (n ¼ 102) of patients who achieved PR. Figure 1 . Kaplan-Meier estimates of OS in (A) all patients and (B) treatment-naive patients and estimates of PFS a based on irRC (investigator review) [21] in (C) all patients and (D) treatment-naive patients. irRC, immune-related response criteria; NR, not reached; OS, overall survival; PFS, progression-free survival. a Two patients who had PD after a first course of pembrolizumab and received a second course of pembrolizumab were not included in this analysis because they did not meet the criteria for confirming progression (i.e. they did not meet the twoimage criterion for timepoint overall response of PD).
In the treatment-naive population, BOR was CR in 38 patients (25%); 40 (27%) achieved PR and 30 (20%) experienced SD, for a DCR of 72% (Table 1) . BOR in 32 patients (21%) was PD. Median time to response was 2.8 months (range: 2.5-32.0), and median duration of response was NR (range: 1.3þ to 60.8þ months) (supplementary Figure S1B , available at Annals of Oncology online). Of the 38 patients who achieved CR, median time to response was 2.8 months (range: 2.5-8.3), and median duration of response was NR (range: 6.0þ to 60.8þ months). Response was ongoing in 35 patients (92%) at the time of data cut-off. Of the 40 who achieved PR, median time to response was 2.8 months (range: 2.5-32.0), and median duration of response was NR (range: 1.3þ to 51.4þ months). Response was ongoing in 29 treatment-naive patients (73%) who achieved PR.
Response by prior ipilimumab treatment was also evaluated (supplementary Table S3 , available at Annals of Oncology online). The overall response rate was slightly higher in ipilimumab-naive patients (46%) than in ipilimumab-exposed patients (36%); DCR was similar between groups (66% and 64%, respectively).
Seventy-two patients who met eligibility criteria for stopping pembrolizumab discontinued treatment to enter observation, per the protocol. Sixty-seven achieved CR and 5 achieved PR as BOR. Median time to first response for them was 2.8 months (range: 0.5-13.8) after treatment initiation. Seven patients had PD (6 CR, 1 PR) after stopping pembrolizumab; most (90%) responses were maintained (Figure 2) . Four patients, all who achieved CR as a first response, received second-course pembrolizumab (Table 2) . BOR on second-course treatment was 1 CR and 1 SD (patient achieved a PR of 2 weeks after data cut-off); 2 had subsequent PD.
Analysis of the 18-gene GEP demonstrated an association between GEP score and overall response to pembrolizumab (supplementary Figure S2A , available at Annals of Oncology online) in treatment-naive and treatment-exposed patients (supplementary Figure S2B , available at Annals of Oncology online) and in ipilimumab-naive and ipilimumab-exposed patients (supplementary Figure S2C , available at Annals of Oncology online).
Treatment-related AEs occurred in 562 patients (86%) (supplementary Table S4 , available at Annals of Oncology online); 114 (17%) experienced grade 3-4 treatment-related AEs, 65 (10%) discontinued because of a treatment-related AE and none experienced treatment-related death. Immune-mediated AEs are shown in supplementary Figure S3 , available at Annals of Oncology online.
Discussion
In this analysis of patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001, the estimated OS rate at 5 years in the overall population and in those who were treatment-naive was comparable to the 4-year OS rate. The percentage of patients with an ongoing response was higher in those who were treatment-naive than in all patients and numerically higher in patients who achieved CR than in those who achieved PR. DCR was unaffected by prior ipilimumab exposure. These data, which represent the longest follow-up of pembrolizumab published in any cancer histology to date, confirm the durable antitumor activity of pembrolizumab in advanced and metastatic melanoma. The safety profile of pembrolizumab in patients with melanoma has been established partly through KEYNOTE-001; with continued follow-up, no new safety signals have been identified in this study.
Five-year OS rates observed with pembrolizumab in this analysis were significantly higher than those reported for ipilimumab monotherapy (12.3%-28.4%) [23] . They represent the first longterm follow-up data from a trial evaluating pembrolizumab in patients with advanced and metastatic melanoma. As with the results presented here [pembrolizumab, 5-year OS rates: 34% (all patients) versus 41% (treatment-naive patients)], slightly higher 5-year survival rates were achieved with ipilimumab in treatment-naive patients [ipilimumab, 5-year OS rates: 12.3%-28.4% (all patients) versus 21.4%-49.5% (treatment-naive patients)]. Single-agent nivolumab demonstrated an OS rate of 34% and median OS of 17.3 months after 45-months' followup in heavily pretreated patients with advanced melanoma [20] . A plateau in OS was seen at approximately 48 months, indicative of a long-term benefit in some patients [20] . In the phase III KEYNOTE-006 trial in which a head-to-head comparison of ipilimumab and pembrolizumab was conducted, 48-month OS rates were 42% with pembrolizumab and 34% with ipilimumab (manuscript in preparation), confirming the superiority of anti-PD-1 therapy in the first-line setting over anti-CTLA-4 and other standard therapies. This assertion is further supported by the robust duration of response.
Previous work has demonstrated correlation between pembrolizumab response rate, PFS, and OS and pretreatment PD-L1 expression in tumor biopsies from patients in KEYNOTE-001, although patients with PD-L1-negative tumors may also achieve durable responses [24] . At the molecular level, long-term responses observed with pembrolizumab in KEYNOTE-001 may be explained by induction of several cytolysis-associated and natural killer-associated genes in the tumor through PD-1 [25] . In patients treated with pembrolizumab for advanced/metastatic melanoma, long-term responses may be maintained through prominent expansion of CD8 þ memory cells [26] . In the present analysis, the distribution of 18-gene GEP scores [22] was higher in responders than in nonresponders, regardless of previous exposure to any treatment, including ipilimumab.
Data are limited describing outcomes in patients who experience disease progress and are retreated with a second course of checkpoint inhibitor therapy. In a retrospective review of 8 patients retreated with nivolumab, response on first-course treatment was 3 CR along with 3 SD before therapy was discontinued (due to PD in 7 patients and grade 3 colitis in 1 patient) [27] . The median nivolumab treatment period was 4.3 months. Following retreatment, 2 patients (25%) achieved PR and 3 (38%) achieved SD, for a response rate of 25% (2 patients) and DCR of 62% (5/8 patients). In another study of nivolumab (N ¼ 107), all 5 patients who discontinued treatment for 100 days and experienced subsequent disease progression achieved durable disease control and were alive at 5 years [20] . In a preliminary analysis of the CA184-025 study evaluating ipilimumab in advanced melanoma (N ¼ 855), 51 patients (6%) who achieved disease control were retreated on disease progression [28] . Of these, 28 (55%) regained disease control and 42% were alive 2 years after the first induction dose. In a follow-up analysis involving 122 patients, 7 (6%) achieved CR and 21 (17%) achieved PR for a BOR rate of 23%. Another 31 (25%) patients achieved SD for a DCR of 48% [23] . Although patient numbers were low, survival outcomes of patients who received second-course pembrolizumab in KEYNOTE-001 compare favorably with those of other immunotherapies; 1 patient each achieved CR and SD (PR documented 2 weeks after data cut-off). Second-course pembrolizumab treatment was also recently assessed in the phase III KEYNOTE-006 study of patients with ipilimumab-naive advanced melanoma. Of the eight patients (first-course responses: 3 CR, 4 PR, 1 SD) who received second-course pembrolizumab, 1 achieved CR, 3 achieved PR, 3 had SD, and 1 had PD [29] . This study reports second-course pembrolizumab in patients with advanced melanoma, and it underscores the role of reinduction as appropriate next-line therapy for patients who experience initial benefit with pembrolizumab therapy.
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